Let’s start up with the current stock price of Acorda Therapeutics Inc. (ACOR), which is $0.52 to be very precise. The Stock rose vividly during the last session to $0.6396 after opening rate of $0.5847 while the lowest price it went was recorded $0.5225 before closing at $0.62.Recently in News on June 16, 2022, Esteve Launches INBRIJA® in Germany. Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. (1). You can read further details here
Acorda Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.6000 on 01/04/22, with the lowest value was $0.2763 for the same time period, recorded on 06/03/22.
Acorda Therapeutics Inc. (ACOR) full year performance was -89.23%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Acorda Therapeutics Inc. shares are logging -91.78% during the 52-week period from high price, and 89.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.28 and $6.36.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1767209 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Acorda Therapeutics Inc. (ACOR) recorded performance in the market was -78.14%, having the revenues showcasing -70.65% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 6.75M, as it employees total of 118 workers.
Analysts verdict on Acorda Therapeutics Inc. (ACOR)
During the last month, 0 analysts gave the Acorda Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.3613, with a change in the price was noted -1.19. In a similar fashion, Acorda Therapeutics Inc. posted a movement of -69.44% for the period of last 100 days, recording 1,053,968 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ACOR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.43.
Acorda Therapeutics Inc. (ACOR): Technical Analysis
Raw Stochastic average of Acorda Therapeutics Inc. in the period of last 50 days is set at 17.67%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 48.01%. In the last 20 days, the company’s Stochastic %K was 61.47% and its Stochastic %D was recorded 66.37%.
Let’s take a glance in the erstwhile performances of Acorda Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -78.14%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -78.67%, alongside a downfall of -89.23% for the period of the last 12 months. The shares increased approximately by 51.49% in the 7-day charts and went up by 1.46% in the period of the last 30 days. Common stock shares were lifted by -70.65% during last recorded quarter.